FINWIRES · TerminalLIVE
FINWIRES

調査速報:Lea:第1四半期決算は市場予想を大幅に上回る。2026年の業績見通しは維持。

By

-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。リア・コーポレーション(LEA)は、第1四半期の調整後EPSが3.87ドルとなり、市場予想の3.12ドル(24%増)を大きく上回りました。売上高は5%増の58億2,000万ドル(市場予想を2,000万ドル下回る)、売上総利益率は120ベーシスポイント上昇し7.7%(市場予想を20ベーシスポイント下回る)となりました。この好業績は、自社株買いによる株式数減少が要因です。LEAは第1四半期に7,500万ドル相当の自社株買いを実施し、平均株式数は前年同期比で5%減少しました。LEA最大の市場である欧州・アフリカ(第1四半期の売上高全体の40%を占める)では、車両1台当たりの部品搭載量が前年同期比で7.5%と大幅に増加した一方、北米では4.1%減少しました。北米での販売減少は様々な要因が複合的に影響しているようで、欧州・アフリカでの販売増加は車両1台あたりの安全性と装備の向上という長期的なトレンドと一致しています。LEAは通期業績見通しを全て維持しました。LEA株は発表後、プレマーケット取引で現在3%上昇しています。第1四半期の業績が予想を大きく上回ったことから、同社が今年後半に通期業績見通しを引き上げる可能性は大幅に高まったと考えています。

Related Articles

Research

Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.

$INCY
Australia

GSK's Linerixibat Gets UK Nod for Itch Linked to Biliary Disease

GSK's (GSK) Linerixibat, to be marketed as Lynavoy, has been approved by the UK's Medicines and Healthcare products Regulatory Agency for the treatment of itching in adults with primary biliary cholangitis, the agency said Friday.The oral therapy aims to reduce bile acid buildup linked to the rare liver disease, which can cause persistent itching, the agency said.The approval was supported by phase 3 data showing Linerixibat significantly reduced itching and improved sleep disruption compared with placebo, it added.Shares of GSK were down 1.2% in Friday trading.Price: $52.01, Change: $-0.30, Percent Change: -0.57%

$GSK
International

ISM US Manufacturing Index Indicates Steady Expansion in April

The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.